Literature DB >> 11698298

Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia.

C Wang1, L R Chiarelli, P Bianchi, D J Abraham, A Galizzi, A Mattevi, A Zanella, G Valentini.   

Abstract

Human erythrocyte pyruvate kinase plays an important role in erythrocyte metabolism. Mutation on the gene results in pyruvate kinase deficiency and is an important cause of hereditary nonspherocytic hemolytic anemia. Because of difficulties in isolating the mutant enzymes from patients, these mutations have not been fully studied. In this study, a complementary DNA (cDNA) encoding the human erythrocyte pyruvate kinase was generated. The cDNA was cloned into several expression vectors, and the protein was expressed and purified. The tetrameric protein exhibited properties characteristic of authentic human erythrocyte pyruvate kinase, including response to substrate, phosphoenolpyruvate, activation by fructose 1,6-bisphosphate, and inhibition by adenosine triphosphate (ATP). The N-terminal segment of the protein was highly susceptible to proteolysis, but only 2 of the 4 subunits were cleaved and lacked 47 N-terminal amino acid residues. A mutant protein, R510Q, which is the most frequently occurring mutation among Northern European population, was also generated and purified. The mutant protein retained its binding capacity to and could be activated by fructose 1,6-bisphosphate and showed similar kinetics toward phosphoenolpyruvate and adenosine diphosphate as for the wild-type enzyme. Conversely, the mutant protein has a dramatically decreased stability toward heat and is more susceptible to ATP inhibition. The enzyme instability decreases the enzyme level in the cell, accounting for the clinically observed "pyruvate kinase deficiency" of patients who are homozygous for this mutation. This study provides the first detailed functional characterization of human erythrocyte pyruvate kinase. These findings will allow the establishment of a fine correlation between molecular abnormalities and the clinical expression of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698298     DOI: 10.1182/blood.v98.10.3113

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Identification of pyruvate kinase in methicillin-resistant Staphylococcus aureus as a novel antimicrobial drug target.

Authors:  Roya Zoraghi; Raymond H See; Peter Axerio-Cilies; Nag S Kumar; Huansheng Gong; Anne Moreau; Michael Hsing; Sukhbir Kaur; Richard D Swayze; Liam Worrall; Emily Amandoron; Tian Lian; Linda Jackson; Jihong Jiang; Lisa Thorson; Christophe Labriere; Leonard Foster; Robert C Brunham; William R McMaster; B Brett Finlay; Natalie C Strynadka; Artem Cherkasov; Robert N Young; Neil E Reiner
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

2.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme.

Authors:  Nestor W Meza; Maria E Alonso-Ferrero; Susana Navarro; Oscar Quintana-Bustamante; Antonio Valeri; Maria Garcia-Gomez; Juan A Bueren; Jose M Bautista; Jose C Segovia
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

3.  Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency.

Authors:  Paola Bianchi; Elisa Fermo; Kimberly Lezon-Geyda; Eduard J van Beers; Holmes D Morton; Wilma Barcellini; Bertil Glader; Satheesh Chonat; Yaddanapudi Ravindranath; Peter E Newburger; Nina Kollmar; Jenny M Despotovic; Madeleine Verhovsek; Mukta Sharma; Janet L Kwiatkowski; Kevin H M Kuo; Marcin W Wlodarski; Hassan M Yaish; Susanne Holzhauer; Heng Wang; Joachim Kunz; Kathryn Addonizio; Hasan Al-Sayegh; Wendy B London; Oliver Andres; Richard van Wijk; Patrick G Gallagher; Rachael F F Grace
Journal:  Am J Hematol       Date:  2020-03-06       Impact factor: 10.047

4.  AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Authors:  Charles Kung; Jeff Hixon; Penelope A Kosinski; Giovanni Cianchetta; Gavin Histen; Yue Chen; Collin Hill; Stefan Gross; Yaguang Si; Kendall Johnson; Byron DeLaBarre; Zhiyong Luo; Zhiwei Gu; Gui Yao; Huachun Tang; Cheng Fang; Yingxia Xu; Xiaobing Lv; Scott Biller; Shin-San Michael Su; Hua Yang; Janeta Popovici-Muller; Francesco Salituro; Lee Silverman; Lenny Dang
Journal:  Blood       Date:  2017-07-31       Impact factor: 22.113

5.  The pH dependence of the allosteric response of human liver pyruvate kinase to fructose-1,6-bisphosphate, ATP, and alanine.

Authors:  Aron W Fenton; Myra Hutchinson
Journal:  Arch Biochem Biophys       Date:  2009-01-20       Impact factor: 4.013

6.  Structures of pyruvate kinases display evolutionarily divergent allosteric strategies.

Authors:  Hugh P Morgan; Wenhe Zhong; Iain W McNae; Paul A M Michels; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  R Soc Open Sci       Date:  2014-09-24       Impact factor: 2.963

7.  PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation.

Authors:  Tong Li; Jinbo Han; Liangjie Jia; Xiao Hu; Liqun Chen; Yiguo Wang
Journal:  Protein Cell       Date:  2019-03-18       Impact factor: 14.870

Review 8.  Regulation of pyruvate metabolism and human disease.

Authors:  Lawrence R Gray; Sean C Tompkins; Eric B Taylor
Journal:  Cell Mol Life Sci       Date:  2013-12-21       Impact factor: 9.261

9.  Modulation of Malaria Phenotypes by Pyruvate Kinase (PKLR) Variants in a Thai Population.

Authors:  Rebekah van Bruggen; Christian Gualtieri; Alexandra Iliescu; Chalisa Louicharoen Cheepsunthorn; Punchalee Mungkalasut; Jean-François Trape; David Modiano; Bienvenu Sodiomon Sirima; Pratap Singhasivanon; Mark Lathrop; Anavaj Sakuntabhai; Jean-François Bureau; Philippe Gros
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

Review 10.  Molecular heterogeneity of pyruvate kinase deficiency.

Authors:  Paola Bianchi; Elisa Fermo
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.